These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 19200274)
1. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients. Tagboto S; Cropper L; Turner J; Pugh-Clarke K J Ren Care; 2009 Mar; 35(1):18-23. PubMed ID: 19200274 [TBL] [Abstract][Full Text] [Related]
2. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Macdougall IC Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980 [TBL] [Abstract][Full Text] [Related]
3. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Van Wyck DB; Martens MG; Seid MH; Baker JB; Mangione A Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600 [TBL] [Abstract][Full Text] [Related]
4. Iron therapy in chronic kidney disease: current controversies. Kovesdy CP; Kalantar-Zadeh K J Ren Care; 2009 Dec; 35 Suppl 2():14-24. PubMed ID: 19891681 [TBL] [Abstract][Full Text] [Related]
5. Evolution of iv iron compounds over the last century. Macdougall IC J Ren Care; 2009 Dec; 35 Suppl 2():8-13. PubMed ID: 19891680 [TBL] [Abstract][Full Text] [Related]
6. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease. Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851 [TBL] [Abstract][Full Text] [Related]
7. Use of intravenous iron supplementation in chronic kidney disease: an update. Macdougall IC; Geisser P Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137 [TBL] [Abstract][Full Text] [Related]
8. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342 [TBL] [Abstract][Full Text] [Related]
9. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534 [TBL] [Abstract][Full Text] [Related]
10. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients. Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014 [TBL] [Abstract][Full Text] [Related]
11. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. Toblli JE; Di Gennaro F PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811 [TBL] [Abstract][Full Text] [Related]
12. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Seid MH; Derman RJ; Baker JB; Banach W; Goldberg C; Rogers R Am J Obstet Gynecol; 2008 Oct; 199(4):435.e1-7. PubMed ID: 18928998 [TBL] [Abstract][Full Text] [Related]
13. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. Szczech LA; Bregman DB; Harrington RA; Morris D; Butcher A; Koch TA; Goodnough LT; Wolf M; Onken JE Nephrol Dial Transplant; 2010 Jul; 25(7):2368-75. PubMed ID: 20466657 [TBL] [Abstract][Full Text] [Related]
14. An evidence-based approach to anaemia management in predialysis chronic kidney disease. Pugh-Clarke K; Cooper L; Turner J; Fermin J J Ren Care; 2009 Dec; 35 Suppl 2():29-31. PubMed ID: 19891683 [TBL] [Abstract][Full Text] [Related]
15. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137 [TBL] [Abstract][Full Text] [Related]
16. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Onken JE; Bregman DB; Harrington RA; Morris D; Buerkert J; Hamerski D; Iftikhar H; Mangoo-Karim R; Martin ER; Martinez CO; Newman GE; Qunibi WY; Ross DL; Singh B; Smith MT; Butcher A; Koch TA; Goodnough LT Nephrol Dial Transplant; 2014 Apr; 29(4):833-42. PubMed ID: 23963731 [TBL] [Abstract][Full Text] [Related]
17. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271 [TBL] [Abstract][Full Text] [Related]
18. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD; BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881 [TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Bailie GR; Mason NA; Valaoras TG Hemodial Int; 2010 Jan; 14(1):47-54. PubMed ID: 19888949 [TBL] [Abstract][Full Text] [Related]
20. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease]. Romanet T; Bedouch P; Zaoui P Nephrol Ther; 2019 Apr; 15(2):104-109. PubMed ID: 30803900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]